カジノ シークレット 無料 ボーナスhemical to collaborate with a UK-based company on biosensors

Apr. 18, 2016

カジノ シークレット 無料 ボーナスhemical Company （カジノ シークレット 無料 ボーナスhemical） has recently agreed with a UK-based Abingdon Health （"AH"） to develop jointly a next generation point of care multiplexed biosensor device.

カジノ シークレット 無料 ボーナスhemical and Molecular Vision, a subsidiary of AH, have been working together over the past 2 years to develop an easy-to-use compact device for use in a variety of diagnostic applications by integrating the technological strength of each company, i.e. printed electronics technologies and lateral flow devices, respectively. The joint development undertaking which カジノ シークレット 無料 ボーナスhemical and AH have agreed on this time takes over the achievements having resulted from the 2 year-collaboration, allowing the two companies to work on verifying the commercial viability of the device.

With big data being increasingly utilized in medical diagnostics today and given the ever growing demand for connected point of care testing, カジノ シークレット 無料 ボーナスhemical will work closely with AH towards early commercialization of a multiplexed biosensor device.

Company Profile

Name	Abingdon Health Ltd
Location	York, UK
CEO	Chris Yates
Business	Developing, manufacturing and sale of a range of rapid testing products in the area of hematology oncology

Name	Molecular Vision Limited
Location	London, UK
CEO	Chris Yates
Business	Developing disposable medical diagnostic point-of-care devices

Contact

Corporate Communications Dept.
27-1, Shinkawa 2-chome, Chuo-ku, Tokyo, 104-8260, Japan
TEL: +81-3-5543-5102 FAX: +81-3-5543-5901